Anureet C. Copeland, MD

Articles by Anureet C. Copeland, MD

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going

ByAnureet C. Copeland, MD,Carey K. Anders, MD

October 17th 2018

This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.

Latest Updated Articles

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going
Published: October 17th 2018 | Updated:

Anureet C. Copeland, MD

Articles by Anureet C. Copeland, MD

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Addressing Systemic Barriers to Dermatologic Consultation in Oncology Care